Xu Yuan

Xu Yuan is listed in filings as Director at Akero Therapeutics, Inc.. This profile follows SEC Form 4 activity through Dec 9, 2025, including sale activity. Recent filings connect the profile to Akero Therapeutics, Inc. (AKRO), Xilio Therapeutics, Inc. (XLO), and FATE THERAPEUTICS INC (FATE). The current snapshot covers public activity from Jun 17, 2024 to Dec 9, 2025. Reported amounts are shown as $762.5K to $598.5K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.